Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor SAN FRANCISCO, Aug. 22, 2025 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision therapies for...
Hence then, the article about lighthouse pharmaceuticals receives 49 2 million grant from nia to advance phase 2 study of lhp588 for p gingivalis positive alzheimer s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-positive Alzheimer's Disease )
Also on site :
- One person in critical condition following two-vehicle collision on SR-126 at Boosey Road
- Supermarket timings for Boxing Day and New Year revealed for Asda, Tesco, Sainsbury’s, Aldi, Lidl and more
- Trump rants about Epstein in Christmas Day post claiming he dropped ties with sex offender ‘long before it became fashionable’